Detected ·
Orakl Oncology
$34MSeries A
Orakl Oncology, a Gustave Roussy spin-out, raised a $34M Series A co-led by Norrsken VC and Singular to make cancer drug response predictable before clinical trials.
- Website
- —
- linkedin.com/company/85957194
- Amount
- $34 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-12 14:56:59 UTC
- Signal ID
- 73fd0981-a5a0-412b-b6db-2d7f68327929
As the API returns it
{
"id": "73fd0981-a5a0-412b-b6db-2d7f68327929",
"created_at": "2026-11-12T14:56:59.559218Z",
"company_name": "Orakl Oncology",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/85957194",
"event_type": "funding",
"funding_amount": 34000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Orakl Oncology, a Gustave Roussy spin-out, raised a $34M Series A co-led by Norrsken VC and Singular to make cancer drug response predictable before clinical trials.*"
}